NasdaqGM - Nasdaq Real Time Price ? USD Candel Therapeutics, Inc. (CADL) Follow Compare 6.06 +0.19 (+3.24%) At close: October 18 at 4:00 PM EDT 6.15 +0.09 (+1.49%) After hours: October 18 at 7:17 PM EDT All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Candel Therapeutics to Present Preclinical Data on Therapeutic Potential of CAN-3110 in Melanoma at SITC 2024 Annual Meeting NEEDHAM, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the Company will present a poster at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting taking place November 6-10, 2024 in Houston, Texas and virtually. Presentation details are as follows: Title: Therapeutic potent GlobeNewswire ? 15 days ago CADL +3.24% Candel Therapeutics, Inc. (NASDAQ:CADL) most popular amongst individual investors who own 48%, insiders hold 30% Key Insights The considerable ownership by individual investors in Candel Therapeutics indicates that they collectively... Simply Wall St. ? last month CADL +3.24% Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors MONTREAL and CHARLOTTE, N.C., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Milestone? Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the appointment of Joseph Papa to its Board of Directors (“Board”), effective September 3, 2024. Mr. Papa is a renowned pharmaceutical and healthcare leader, with more than 35 years of experience navigating companies through periods of rapid growth, tran GlobeNewswire ? last month MIST CADL +3.24% EBS Candel Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference NEEDHAM, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that Paul Peter Tak, MD, PhD, FMedSci, Candel’s President and Chief Executive Officer, will present at the 26th Annual Global Investment Conference being held in-person and virtually on September 9-11, 2024. Time:Available from 7:00 GlobeNewswire ? last month CADL +3.24% Candel Therapeutics Reports Second Quarter 2024 Financial Results?and Recent Corporate Highlights Announced positive survival data from the phase 2 randomized controlled clinical trial of CAN-2409 in borderline resectable pancreatic cancerPresented positive topline overall survival data from the phase 2 clinical trial of CAN-2409 in non-small cell lung cancer (NSCLC) at 2024 American Society of Clinical Oncology (ASCO) Annual MeetingReceived orphan drug designation from the U.S. Food and Drug Administration (FDA) for both CAN-2409 and CAN-3110, for the treatment of pancreatic cancer and recu GlobeNewswire ? 2 months ago CADL +3.24% Candel Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference NEEDHAM, Mass., June 18, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that Paul Peter Tak, MD, PhD, FMedSci, Candel’s President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference on Tuesday, June 25, 2024 at 3:00 p.m. GlobeNewswire ? 3 months ago CADL +3.24% Candel Therapeutics' (NASDAQ:CADL) enLIGHTEN Discovery Platform Aims To Tackle Complexities Of Tumor Microenvironments By Jeremy Golden, Benzinga NEEDHAM, MA / ACCESSWIRE / June 14, 2024 /Candel Therapeutics, Inc. (NASDAQ:CADL) is helping pioneer the next generation of viral immunotherapy by leveraging a data-driven approach to create new assets and further the development ... ACCESSWIRE ? 4 months ago CADL +3.24% 7 A-Rated Biotech Stocks Worth Betting on in June Let me be clear: investing in biotech stocks isn’t for everyone. Investing in smaller biotech companies requires research, patience, and risk tolerance. Investing in A-rated biotech stocks offers high return potential if they make significant advancements in health care. Biotech stocks represent companies that are involved in the research and development of drugs, therapies and medical devices. They include companies that work in fields such as genomics, biopharmaceuticals, bioinformatics and me InvestorPlace ? 4 months ago LLY OCGN NVO Candel Therapeutics to Join Russell 3000? Index NEEDHAM, Mass., June 11, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that the Company is set to join the broad-market Russell 3000 Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024, according to a preliminary GlobeNewswire ? 4 months ago CADL +3.24% Candel Therapeutics (NASDAQ: CADL) Reports Positive Data From Phase 2 Trial Of CAN-2409 In Borderline Resectable Pancreatic Cancer By Jeremy Golden, Benzinga NEEDHAM, MA / ACCESSWIRE / June 3, 2024 / Clinical-stage biopharmaceutical company Candel Therapeutics, Inc. (NASDAQ:CADL) reported updated survival data from its randomized phase 2 clinical trial of CAN-2409 in borderline ... ACCESSWIRE ? 4 months ago CADL +3.24% FDA Grants Orphan Drug Designation for CAN-3110 for the Treatment of Recurrent High-Grade Glioma FDA Orphan Designation provides CAN-3110 certain developmental financial incentives, with potential for up to 7 years of marketing exclusivity in the United States, if approvedCAN-3110 phase 1b data on the feasibility and safety of multiple doses of CAN-3110 will be featured in poster presentation at 2024 ASCO Annual Meeting NEEDHAM, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on deve GlobeNewswire ? 4 months ago CADL +3.24% Candel (CADL) Stock Skyrockets 431% Year to Date: Here's Why Candel (CADL) surges 431% in the year-to-date period, driven by positive developmental and regulatory updates from the clinical program for CAN-2409 across two different cancer indications. Zacks ? 4 months ago CADL +3.24% ALXO Candel (CADL) Reports Upbeat Data From Lung Cancer Study Candel's (CADL) CAN-2409 prolongs overall survival in a phase II study for treating patients with advanced non-small cell lung cancer who are non-responsive to immune checkpoint inhibitor therapy. Zacks ? 4 months ago CADL +3.24% Candel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of CAN-2409 for Advanced Non-Small Cell Lung Cancer (NSCLC) in Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment at 2024 ASCO Annual Meeting Median overall survival of 20.6 months was observed following two administrations of CAN-2409 + valacyclovir in NSCLC patients with progressive disease despite immune checkpoint inhibitor therapy compared to published results of median overall survival of 11.6 months observed with standard of care docetaxel-based chemotherapy in a similar patient populationCAN-2409 treatment resulted in activation of the systemic immune response after two administrations of CAN-2409, including increased numbers GlobeNewswire ? 4 months ago CADL +3.24% Candel Therapeutics to Present at the Jefferies Global Healthcare Conference NEEDHAM, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that Paul Peter Tak, MD, PhD, FMedSci, Candel’s President and Chief Executive Officer, will present a company overview at the Jefferies Global Healthcare Conference on Wednesday, June 5, 2024 at 5:30 p.m. ET. A live webcast of the pres GlobeNewswire ? 4 months ago CADL +3.24% Candel Therapeutics to Host Non-Small Cell Lung Cancer (NSCLC) R&D Breakfast Panel During 2024 ASCO Annual Meeting Management and scientific/medical thought leaders to discuss topline overall survival data from phase 2 clinical trial of CAN-2409 in NSCLCNEEDHAM, Mass., May 20, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced it will be hosting a webcasted R&D breakfast panel featuring prominent scientific and medical th GlobeNewswire ? 4 months ago CADL +3.24% Candel Therapeutics Reports First Quarter 2024 Financial Results?and Recent Corporate Highlights Announced positive survival data from ongoing randomized phase 2 clinical trial of CAN-2409 in borderline resectable pancreatic cancerPhase 2 topline overall survival data for CAN-2409 in non-small cell lung cancer (NSCLC), to be presented at ASCO on June 3, 2024On track for topline disease-free survival data from CAN-2409 phase 3 clinical trial in localized intermediate/high risk prostate cancer, expected in Q4 2024 NEEDHAM, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Can GlobeNewswire ? 5 months ago CADL +3.24% Candel Therapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting NEEDHAM, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that two abstracts were accepted for presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 31 to June 4, 2024, in Chicago, IL. The first presentation will feature data from the ongoing GlobeNewswire ? 5 months ago CADL +3.24% Candel (CADL) Up as Pancreatic Cancer Drug Gets Orphan Drug Tag Candel (CADL) rallies 43% as the FDA grants the orphan drug designation to its lead candidate, CAN-2409, for treating non-metastatic pancreatic cancer. Zacks ? 6 months ago CADL +3.24% ANVS Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer NEEDHAM, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to CAN-2409, Candel’s most advanced multimodal biological immunotherapy candidate, for the treatment of pancreatic cancer. “We recently reported dat GlobeNewswire ? 6 months ago CADL +3.24% Performance Overview Trailing total returns as of 10/18/2024, which may include dividends or other distributions. Benchmark is S&P 500 Return CADL S&P 500 YTD +312.24% +22.95% 1-Year +573.33% +34.10% 3-Year -38.35% +31.16%
